Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intermune's 'minor improvement' gets $25k-a-year price in France

This article was originally published in Scrip

Executive Summary

Intermune is "very, very pleased" with its French price for its orphan drug Esbriet (pirfenidone) for mild to moderate idiopathic pulmonary fibrosis. CEPS, France's pricing committee has approved an ex-factory price of €25,000 per patient per year, which is on a par with the price of Actelion's Tracleer (bosentan). It is also higher than prices approved for Novartis' Gilenya and Elan/Biogen's Tysabri (natalizumab), both for MS, €22,700 and €23,500 respectively.

You may also be interested in...



Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Voluntary EU Joint Clinical Assessments ‘Risk Access To Medicines’

Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018735

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel